EMA Recommends Granting a Marketing Authorisation for Ensartinib By Ogkologos - October 9, 2026 200 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with ALK-positive, advanced NSCLC Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative... February 27, 2025 Targeted Therapy–Immunotherapy Combinations Effective for Advanced Kidney Cancer March 19, 2019 For People with Cancer, Are Steroids the Best Treatment for Breathing... October 25, 2022 Deputy Spends His Days Off Teaching Life Skills To Young Boys... December 26, 2021 Load more HOT NEWS FDA Approves Ivosidenib for Myelodysplastic Syndromes Sparing the Hippocampus During PCI Better Preserves Cognitive Function in Patients... Neoadjuvant Camrelizumab Plus Chemotherapy Demonstrate Superior pCR Compared to Chemotherapy Alone... Altering Diet Enhances Response to Cancer Treatments in Mice
